UROGEN PHARMA LTDNARY SHARES
UROGEN PHARMA LTDNARY SHARES
Share · IL0011407140 · URGN · A2DTCV (XNMS)
Overview
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
11
4
0
0
No Price
30.01.2026 21:00
Current Prices from UROGEN PHARMA LTDNARY SHARES
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
URGN
USD
30.01.2026 21:00
19,61 USD
-1,08 USD
-5,22 %
XDQU: Quotrix
Quotrix
UGPLRS40.DUSD
EUR
30.01.2026 14:19
17,60 EUR
0,20 EUR
+1,15 %
XFRA: Frankfurt
Frankfurt
UR8.F
EUR
30.01.2026 07:13
16,90 EUR
-0,50 EUR
-2,87 %
XDUS: Düsseldorf
Düsseldorf
UGPLRS40.DUSB
EUR
29.01.2026 18:30
16,90 EUR
-0,90 EUR
-5,06 %
Share Float & Liquidity
Free Float 82,68 %
Shares Float 38,7 M
Shares Outstanding 46,81 M
Invested Funds

The following funds have invested in UROGEN PHARMA LTDNARY SHARES:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
12,49
Percentage (%)
0,03 %
Company Profile for UROGEN PHARMA LTDNARY SHARES Share
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
AI Analysis of UROGEN PHARMA LTDNARY SHARES
Click any analysis below to get instant AI insights from finAgent
Latest AI Analyses of UROGEN PHARMA LTDNARY SHARES
No AI threads available for this company yet.

Company Data

Name UROGEN PHARMA LTDNARY SHARES
Company UroGen Pharma Ltd.
Symbol URGN
Website https://www.urogen.com
Primary Exchange XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A2DTCV
ISIN IL0011407140
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Elizabeth A. Barrett
Market Capitalization 918 Mio
Country United States of America
Currency USD
Employees 0,2 T
Address 400 Alexander Park, 08540 Princeton
IPO Date 2017-05-04

Ticker Symbols

Name Symbol
Düsseldorf UGPLRS40.DUSB
Frankfurt UR8.F
NASDAQ URGN
Quotrix UGPLRS40.DUSD
More Shares
Investors who hold UROGEN PHARMA LTDNARY SHARES also have the following shares in their portfolio:
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
AUTOMATIC DATA PROCESSING INC
AUTOMATIC DATA PROCESSING INC Share
BZRX
BZRX Crypto
CANADA 21/26
CANADA 21/26 Bond
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
HONEYWELL INTERNATIONAL INC
HONEYWELL INTERNATIONAL INC Share
INTEL CORP
INTEL CORP Share
MICROSOFT CORP
MICROSOFT CORP Share
MONEGA FAIRINVEST AKTI.R
MONEGA FAIRINVEST AKTI.R Fund
Pazoo, Inc.
Pazoo, Inc. Share
QIAGEN NV (alt)
QIAGEN NV (alt) Share
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2026